BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC.

WINCHESTER, MA

OncologyGrant-only

What changed

NIH R21 · $0.1M · Sequential infection of laboratory mice for enhanced cancer and immunotherapy translation

12mo agoNew grantJul 23, 2025Source filing (opens the source filing in a new tab)

Momentum

36no change

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R21 · $139k · non-dilutive
Aug 1, 2025
UNIVERSITY HEALTH NETWORK · PI BROOKS, DAVID G · NCI · award ends Jul 31, 2027 · Sequential infection of laboratory mice for enhanced cancer and immunotherapy translation
NIH RePORTER · NIH RePORTER 11203226 (opens the source filing in a new tab)
Grant
R44 · $2.4M · non-dilutive
Sep 1, 2021
BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC. · PI BROOKS, DAVID G · NCI · award ends Jun 30, 2027 · Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
NIH RePORTER · NIH RePORTER 11131238 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 79%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R21 · $0.1M · Sequential infection of laboratory mice for enhanced cancer and immunotherapy translation
12mo agoNew grantSource (opens the source filing in a new tab)
NIH R44 · $2.4M · Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
Jul 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R21 · $139k · non-dilutive

R44 · $2.4M · non-dilutive